Innovative Health Diagnostics (IHD), a CLIA- and FDA-certified lab that empowers every person access to accurate, clinical testing by providing testing when and where it matters most, announced today a new partnership with AIMA Laboratories (AIMA), a Hamilton-based FemTech company dedicated to developing new products that fill current gaps in gynecological health, to develop and deliver a new and reliable at-home blood test to detect endometriosis.
Endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility. For the roughly 10% of reproductive-age women and girls globally who have endometriosis – approximately 190 million – there is a significant gap between when symptoms first appear and when they are diagnosed, which can typically take around 5 to 12 years.
“We’re thrilled to partner with AIMA to offer a service that provides actionable results and allows millions of women access to early diagnostic tools to detect endometriosis, carving a path to the right care, at the right time and when it’s most convenient,” said David White, IHD CEO and Co-Founder. “At IHD, our mission is to deliver solutions that provide hope to people struggling with infertility, and our partnership with AIMA further enables that mission.”
The new IHD-AIMA test will complement laparoscopic procedures. The test will both help eliminate diagnostic delays, enabling a noninvasive way to test for endometriosis, and allow for patients who receive a positive test result to undergo a laparoscopy for treatment potentially years sooner than they would otherwise.
Read the full press release here